Mode
Text Size
Log in / Sign up
Phase 3 Completed N=47 Treatment

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

MDD
Source: ClinicalTrials.gov NCT02013609 ↗
Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Mar 2016
Primary outcomePrimary: Mean Change From Baseline to Week 12 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score — -18.1 Units on a scale — p=<0.0001
◆ Published Evidence
Established
22citations · ~4 / year
Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews.
Journal of patient-reported outcomes · 2021 · Open access · Likely link

Summary

To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response in a school or work environment.

Linked Publications

  • Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews.
    Journal of patient-reported outcomes · 2021 · 22 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Change From Baseline to Week 12 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score
-18.1 <0.0001 sig
SECONDARY
Mean Change From Baseline to Week 12 in Clinical Global Impression-Severity (CGI-S) Total Score
-2.0 <0.0001 sig
SECONDARY
Mean Clinical Global Impression-Improvement (CGI-I) Score at Week 12
3.5; 3.0; 2.8; 2.7; 2.6; 2.5
SECONDARY
Number of Participants With CGI-I Response
4; 12; 17; 24; 27; 29
SECONDARY
Percentage of Participants With MADRS Response
53.2
SECONDARY
Percentage of Participants With MADRS Remission
42.6
SECONDARY
Mean Change From Baseline to Week 12 in Hamilton Depression Rating Scale (HAM-D17) Total Score
-14.9 <0.0001 sig
SECONDARY
Mean Change From Baseline to Week 12 in Sheehan Disability Scale (SDS) 3-item Total/Summed Score
-3.74 <0.0001 sig
SECONDARY
Mean Change From Baseline to Week 12 in Sheehan Disability Scale (SDS) Single Item Sub-scores
-3.5; -3.9; -3.7 <0.0001 sig
SECONDARY
Mean Change From Baseline to Week 12 in Social Adaptation Self-evaluation Scale (SASS) Total Score
9.7 <0.0001 sig
SECONDARY
Mean Change From Baseline to Week 12 in Massachusetts General Hospital-Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score
-8.1 <0.0001 sig
SECONDARY
Mean Change From Baseline to Week 12 in Kellner Symptom Questionnaire (KSQ) Total Score
-30.5 <0.0001 sig
SECONDARY
Mean Change From Baseline to Week 12 in Go/No-Go Task (P-inhibition Failure)
0.052; 0.052 0.3439
SECONDARY
Mean Change From Baseline to Week 12 in Go/No-Go Task (Mean Reaction Time)
-17.35; -12.99 0.2052
SECONDARY
Mean Change From Baseline in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) k Value
0.009531 0.3169
SECONDARY
Mean Change From Baseline to Week 12 in the Number of Impulsive Choices in the Delayed Reward Task (DRT)
3.6 0.3352
SECONDARY
Mean Change From Baseline to Week 12 in Delay and Probability Discounting Task (DPDT)
21.315241; 10.350419 0.3517
SECONDARY
Mean Change From Baseline in Food Delay Discounting Task (DDT)
0.3487 0.2610
SECONDARY
Mean Change From Baseline in Money Delay Discounting Task
-0.0095 0.8138
SECONDARY
Mean Change From Baseline to Week 12 in Barratt Impulsiveness Scale 11-Item (BIS-11) Total Score
-7.1 <0.0001 sig

Eligibility Criteria

Main Inclusion Criteria: Have a diagnosis of a single or recurrent, nonpsychotic episode of MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by both the Mini International Neuropsychiatric Interview (M.I.N.I.) and an adequate clinical psychiatric evaluation. Have a treatment history of an inadequate ADT response to at least 1 ADT (but not > 3) for the current episode. Have received a single, trial-approved, SSRI or SNRI at an adequate dose for ≥ 6 weeks prior to screening. Are 18 to 35 years old at the time of consent (inclusive, and outpatients only). Are (and will be) working 20 hours or more per week or a student taking 6 credit hours or more during the trial period, however minor deviations from the "part-time" concept may be acceptable on a case-by-case basis based on approval of the medical monitor. Have a Hamilton Depression Rating Scale (HAM-D)- 17-item Total Score ≥ 18 at screening and baseline. Have a Sheehan Disability Scale (SDS) 3-item mean score ≥ 5 at baseline. Main Exclusion Criteria: Subjects with any of the following current Axis I DSM-IV-TR diagnoses: delirium, dementia, amnestic, or other cognitive disorders; schizophrenia, schizoaffective disorder, or other psychotic disorders; bipolar I disorder, bipolar II disorder, or bipolar disorder not otherwise specified (NOS); eating disorders (including anorexia nervosa or bulimia); obsessive compulsive disorder; panic disorder; post-traumatic stress disorder; and attention deficit hyperactivity disorder. Subjects with any of the following current Axis II DSM-IV-TR diagnoses: borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorders, or mental retardation.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02013609) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search